Botanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement

MT Newswires Live09:15

Botanix Pharmaceuticals (ASX:BOT) said it has amended its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.

The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.

Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.

The company's shares fell 2% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623536172?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 09:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623536172","market":"sg","top_or_hot":-1,"title":"Botanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) said it has amended its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.</p><p>The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.</p><p>Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.</p><p>The company's shares fell 2% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Botanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBotanix Pharmaceuticals Defers API Purchases to 2027, 2028 Under Amended Supply Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-30 09:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/BOT.AU\">Botanix Pharmaceuticals</a> (ASX:BOT) said it has amended its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.</p><p>The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.</p><p>Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.</p><p>The company's shares fell 2% in recent Monday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623536172","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623536172","pubTimestamp":1774833312,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Botanix Pharmaceuticals  said it has amended its active pharmaceutical ingredient  supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.The company's shares fell 2% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4023":"应用软件","API":"声网","BK6100":"保健护理服务","BK4535":"淡马锡持仓","BK6520":"工商业服务概念","BK4503":"景林资产持仓","BK7502":"大麻概念","OTX.SI":"迈怡汇有限公司","BK7508":"医药生物股","API.AU":"Australian Pharma Industries","BOT.AU":"BOTANIX PHARMACEUTICALS LTD","BK4551":"寇图资本持仓","BK7103":"保健护理产品经销商","BK7096":"制药"},"translate_title":"根据修订后的供应协议，Botanix Pharmaceuticals将API采购推迟至2027年、2028年","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"API":1,"BOT.AU":1,"API.AU":1,"OTX.SI":1.5},"content_text":"Botanix Pharmaceuticals (ASX:BOT) said it has amended its active pharmaceutical ingredient (API) supply agreement with Kaken Pharmaceutical, rescheduling purchases to December 2027 and December 2028 from the previously set dates for April 2026 and January 2027, according to a Monday Australian bourse filing.The company said following a recent API purchase earlier this month, no further API purchases are required before December 2027, while activities continue to establish an alternate API supplier for Sofpironium Bromide with a view to de-risking the supply chain and achieving potential savings of 25% to 40% in cost of goods sold.Deferring the purchases, in conjunction with proceeds from the current capital raise if approved, is expected to strengthen Botanix's ability to pursue its plans for Sofdra and its fulfillment platform, the filing added.The company's shares fell 2% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623536172","isCrawlerRequest":true}